NCT07672561 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ⅲ Study to Evaluate the Efficacy and Safety of WD-890 Tablets for the Treatment of Moderate to Severe Plaque Psoriasis
| NCT ID | NCT07672561 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Zhejiang Wenda Pharma Technology LTD. |
| Condition | Moderate to Severe Plaque Psoriasis |
| Study Type | INTERVENTIONAL |
| Enrollment | 375 participants |
| Start Date | 2026-03-18 |
| Primary Completion | 2026-11-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 375 participants in total. It began in 2026-03-18 with a primary completion date of 2026-11-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of the study is to evaluate the experimental medication WD-890 compared to placebo in participants with moderate-to-severe plaque psoriasis.
Eligibility Criteria
Inclusion Criteria: * Male or female participant aged 18 to 75 years(inclusive)at the time of informed consent. * Diagnosis of plaque psoriasis for at least 6 months prior to the screening visit. * Body surface area (BSA) ≥10%, Psoriasis Area and Severity Index (PASI) score ≥12 and static Physician's Global Assessment (sPGA) ≥3 at screening visit and randomization Exclusion Criteria: * Participant has a nonplaque form of psoriasis (for example, erythrodermic, guttate, inverse, pustular,or drug induced psoriasis.) * Has uncontrolled arterial hypertension characterized by a systolic blood pressure (BP) ≥160 mm Hg or diastolic BP ≥100 mm Hg Note: Determined by 2 consecutive elevated readings. If an initial BP reading exceeds this limit, the BP may be repeated once after the subject has rested sitting for ≥10 minutes. If the repeat value is less than the criterion limits, the second value may be accepted * Class III or IV congestive heart failure by New York Heart Association Criteria
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07672561 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Moderate to Severe Plaque Psoriasis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07672561 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 375 participants.
Is NCT07672561 currently recruiting?
Yes, NCT07672561 is actively recruiting participants. Contact the research team at qianlu5860@gmail.com for enrollment information.
Where is the NCT07672561 trial being conducted?
This trial is being conducted at Nanjing, China.
Who is sponsoring the NCT07672561 clinical trial?
NCT07672561 is sponsored by Zhejiang Wenda Pharma Technology LTD.. The trial plans to enroll 375 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.